|
Jul 25
|
AstraZeneca Plc (AZN) Q2 2024 Earnings Call Transcript
|
|
Jul 25
|
Why AstraZeneca's CEO isn't worried about costs
|
|
Jul 25
|
Sanofi (SNY) Q2 Earnings Beat, Sales Miss, 2024 View Raised
|
|
Jul 25
|
Astrazeneca (AZN) Reports Q2 Earnings: What Key Metrics Have to Say
|
|
Jul 25
|
NHS spending rules risk depriving Britain of new medicine, warns AstraZeneca boss
|
|
Jul 25
|
AstraZeneca Posts Mixed Q2 Earnings, Still Raises Annual Guidance On Strong Demand For Cancer, Rare Disease Medicines
|
|
Jul 25
|
AstraZeneca (AZN) Beats on Q2 Earnings & Sales, Ups '24 View
|
|
Jun 19
|
AstraZeneca’s Truqap flops in Phase III triple negative breast cancer trial
|
|
Jun 19
|
Admiral Group And Two Other UK Exchange Stocks Estimated As Undervalued For Investment Consideration
|
|
Jun 18
|
AstraZeneca's (AZN) Truqap Misses Endpoints in TNBC Study
|
|
Jun 18
|
Covid-19 Pharma Stars Continue Their Quest To Set New Standards In Cancer Treatment
|
|
Jun 18
|
Sanofi taps Belharra for immune drug research; AstraZeneca’s new cancer drug falls short
|
|
Jun 18
|
One AstraZeneca Insider Raised Stake By 50% In Previous Year
|
|
Jun 17
|
Astrazeneca (AZN) Stock Sinks As Market Gains: Here's Why
|
|
Jun 17
|
EHA 2024: AstraZeneca’s Calquence plus chemoimmunotherapy offers new standard for MCL
|
|
Jun 17
|
AstraZeneca's (AZN) Imfinzi Gets FDA Nod in Expanded Use
|
|
Jun 17
|
IMFINZI® (durvalumab) plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer
|
|
Jun 17
|
AstraZeneca Imfinzi regimen for endometrial cancer gains FDA approval
|
|
Jun 17
|
AstraZeneca reports positive data from Phase III mantle cell lymphoma trial
|
|
Jun 17
|
AstraZeneca/Fibrogen’s Roxadustat FDA Review Further Delayed Following Unanticipated Advisory Committee Request
|